TRANSVAC Funding of SPORCOVAX, SporeGen's Mucosal Vaccine to COVID-19

  • September 14, 2021
  • SporeGen

SporeGen has just received notification to evaluate its candidate mucosal vaccine, SPORCOVAX, to COVID-19 in collaboration with Institute of Agriculture and Food Research and Technology - IRTA (Spain) and funded by TRANSVAC a collaborative infrastructure project under the umbrella of the European Vaccine Initiative (EVI).

The SporeGen approach uses spores of a proprietary strain of B. subtilis that have been engineered to express SARS-Cov-2 antigens.